Teprotumumab

IV methylprednisolone was linked to a small change in proptosis from baseline compared with placebo in patients with thyroid eye disease, while teprotumumab may improve proptosis and diplopia vs. IV methylprednisolone.

AUSTIN, Texas — In this Healio Video Perspective from the North American Neuro-Ophthalmology Society meeting, Prem Subramanian, MD, PhD, discusses the sustained efficacy of teprotumumab in patients with thyroid eye disease.

NEW ORLEANS — In this Healio Video Perspective from the AAO meeting, Raymond Douglas, MD, PhD, discusses results of a clinical trial examining adherence to teprotumumab and reasons for nonadherence in patients with thyroid eye disease.

NEW ORLEANS — Teprotumumab may offer comparable proptosis efficacy in patients with thyroid eye disease with low levels of inflammation as seen in patients with higher levels of inflammatory activity, according to a study.

Teprotumumab is effective in reducing proptosis in people with thyroid eye disease more than 2 years after treatment, and initial nonresponders to teprotumumab may benefit from a second series of infusions, according to a speaker.

Treatment for thyroid eye disease should be personalized, with joint input from endocrinologists and ophthalmologists, according to two speakers.

First-line treatment of thyroid eye disease differs around the globe, with teprotumumab the most commonly prescribed treatment in North America and IV steroids most common in Europe, according to a speaker.

In an update on notable, recently conducted thyroid studies, a speaker reviewed the latest treatments and imaging modalities for children and adults that have the potential to change thyroidology practice.

Not everyone can agree on what to call thyroid eye disease. For some, it is thyroid-associated ophthalmopathy; for others, it is thyroid-related immune orbitopathy. It has also been referred to as Graves’ orbitopathy.

Traditionally, many experts in the field have advocated steroids. More recently, EUGOGO and others have advocated high-dose pulse steroid therapy in TED as that route of administration appears to be less associated with side effects.